Non-AIDS-defining cancers among HIV-infected patients

Current HIV/AIDS Reports

Volumn 10, Issue 3, 2013, Pages 207-216

  Cutrell, James ^a   Bedimo, Roger ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

AIDS; Cancer; HAART; HIV; Non AIDS defining cancers

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ANUS CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CD4 LYMPHOCYTE COUNT; CHRONIC INFLAMMATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFECTION PREVENTION; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MEN WHO HAVE SEX WITH MEN; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MIXED INFECTION; NEOPLASM; NON AIDS DEFINING CANCER; NONHUMAN; OPPORTUNISTIC INFECTION; PROSTATE CANCER; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; TUMOR VIRUS; UNITED STATES; VIRUS HEPATITIS; WART VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84881475411     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0166-8     Document Type: Article

References (99)

1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-8.
2. Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. (Pubitemid 44306484)
3. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR Recomm Rep. 2008;57:1-12.
4. •• Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-62. This study provides U.S. national estimates of annual cancer burden by calculating incident cancers, by cancer type, from 1991 to 2005 in HIV-infected patients with and without AIDS. A dramatic shift in the spectrum of cancers from ADC to NADC occurred, driven by aging and growth of the HIV population.
5. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187-94. (Pubitemid 351705208)
6. Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55:1228-35.
7. • Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51:957-62. This study described cancer-related mortality in a US registry-based cohort of 83,282 AIDS patients from 1980 to 2006. Significant decreases in mortality from ADC and NADC occurred during the HAART era, but due to faster declines in mortality from other AIDS-related deaths, the proportion of deaths from cancers increased, particularly from NHL and lung cancers.
8. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203-8.
9. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611-22.
10. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009;23:875-85.
11. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337-45.
12. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-36. (Pubitemid 351717418)
13. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41-50.
14. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884-90.
15. • Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-22. This update from the Swiss HIV Cohort Study reports SIRs and age-standardized cancer incidence comparing 9429 HIV-infected patients to controls from Swiss cantonal cancer registries in the pre-, early-, and late-HAART periods. Increases in the incidence of select NADC occurred in the early-HAART era, but overall NADC incidence was double that of the general population and remained stable in all periods.
16. • Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24:506-16. This recent review explores in detail the relationship of immunodeficiency, chronic inflammation, and immune activation to cancer risk in HIV-infected patients. The authors also summarize the existing data regarding the relationship of CD4 count to overall NADC rates and specific cancer types, discussing possible explanations for discrepant findings.
17. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406. (Pubitemid 46768570)
18. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-45. (Pubitemid 32259908)
19. Persson EC, Shiels MS, Dawsey SM, et al. Increased risk of stomach and esophageal malignancies in people with AIDS. Gastroenterology. 2012;143:943-50. e942.
20. Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105:350-60.
21. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104:1505-11. (Pubitemid 41356166)
22. Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS. 2013;27:459-68.
23. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527-37. (Pubitemid 47334759)
24. Goedert JJ, Schairer C, McNeel TS, et al. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer. 2006;95:642-8. (Pubitemid 44325906)
25. Levine AM, Seaberg EC, Hessol NA, et al. HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol. 2010;28:1514-9.
26. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026-34.
27. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-32. (Pubitemid 40528605)
28. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527-33. (Pubitemid 36423125)
29. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109-16.
30. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152-9.
31. Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis. 2010;50:1316-21.
32. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306-15.
33. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458-65.
34. Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011;80:42-9.
35. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis. 2004;39:1380-4. (Pubitemid 39458526)
36. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143-53.
37. •• Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-9. This study from the Kaiser Permanente HIV cohort compared cancer risk in 20,775 HIV-infected patients and 215,158 HIV-infected controls from the same healthcare system. After adjustment for demographic and traditional cancer risk factors, elevated RRs were seen for 7 of 10 cancer types studied and an association of lower CD4 count, and elevated risk was seen for 9 of 10 cancer types studied.
38. Harrod R, Nacsa J, Van Lint C, et al. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem. 2003;278:12310-8. (Pubitemid 36800214)
39. De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003;22:6214-9. (Pubitemid 37281651)
40. Wright S, Lu X, Peterlin BM. Human immunodeficiency virus type 1 tat directs transcription through attenuation sites within the mouse c-myc gene. J Mol Biol. 1994;243:568-73. (Pubitemid 24341702)
41. Campioni D, Corallini A, Zauli G, et al. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retroviruses. 1995;11:1039-48.
42. Colombrino E, Rossi E, Ballon G, et al. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res. 2004;295:539-48. (Pubitemid 38490505)
43. Nyagol J, Leucci E, Onnis A, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther. 2006;5:684-90. (Pubitemid 44024724)
44. Altavilla G, Caputo A, Lanfredi M, et al. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol. 2000;157:1081-9.
45. Corallini A, Campioni D, Rossi C, et al. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS. 1996;10:701-10. (Pubitemid 26172772)
46. Wistuba II, Behrens C, Milchgrub S, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 1998;279:1554-9. (Pubitemid 28233011)
47. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285-93. (Pubitemid 39620221)
48. McGinnis KA, Fultz SL, Skanderson M, et al. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006;24:5005-9. (Pubitemid 46631403)
49. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4:52-6.
50. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781-9.
51. Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol. 2000;151:1148-57. (Pubitemid 30451947)
52. Kato T, Koriyama C, Khan N, et al. EGFR mutations and human papillomavirus in lung cancer. Lung Cancer. 2012;78:144-7.
53. Syrjanen K. Detection of human papillomavirus in lung cancer: systematic review and meta-analysis. Anticancer Res. 2012;32:3235-50.
54. Thompson LD, Fisher SI, Chu WS, et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121:727-38. (Pubitemid 38534005)
55. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4:3-10.
56. Wieland U, Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV-positive individuals. Curr Opin Oncol. 2011;23:488-93.
57. Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 2003;5:172-7. (Pubitemid 37336634)
58. Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400-6. (Pubitemid 35013190)
59. Schacker TW, Nguyen PL, Martinez E, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis. 2002;186:1092-7. (Pubitemid 35177111)
60. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67. (Pubitemid 47017468)
61. Plaeger SF, Collins BS, Musib R, et al. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012;28:469-77.
62. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103:1112-22.
63. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
64. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201:1796-805.
65. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep. 2012;9:223-30.
66. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896-903.
67. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383-8. (Pubitemid 46622002)
68. Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103-10. (Pubitemid 46984625)
69. Olivero OA, Tejera AM, Fernandez JJ, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005;20:139-46. (Pubitemid 40637814)
70. Carter MM, Torres SM, Cook Jr DL, et al. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen. 2007;48:239-47. (Pubitemid 46536092)
71. Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2009;51:305-9.
72. Yopp AC, Subramanian M, Jain MK, et al. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol. 2012;10:1284-90.
73. Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54:189-206. quiz 207-110. (Pubitemid 43144386)
74. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138:758-63. (Pubitemid 34625520)
75. • Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26:1017-25. This Veterans Aging Cohort Study compared lung cancer incidence in demographically similar HIV-infected and uninfected veterans. After controlling for smoking, HIV remained an independent risk factor for lung cancer in one of the largest studies to directly examine the contributions of HIV and smoking to lung cancer risk.
76. D'Jaen GA, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010;11:396-404.
77. Gewurz BE, Dezube BJ, Pantanowitz L. HIV and the breast. AIDS Read. 2005;15(392-396):399-402.
78. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer. 2009;8:215-9.
79. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293-9. (Pubitemid 40923208)
80. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr. 2010;55:510-5.
81. • Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111-6. This trial reported on 93 HIV-infected and 131 HIV-uninfected patients with HL treated with aggressive combination chemotherapy from 1997 to 2010. Despite more extensive disease and adverse prognostic factors, HIV-infected patients had similar five-year overall and event-free survival to HIV-negative patients.
82. Abramowitz L, Mathieu N, Roudot-Thoraval F, et al. Epidermoid anal cancer prognosis comparison among HIV + and HIV- patients. Aliment Pharmacol Ther. 2009;30:414-21.
83. Lim C, Goutte N, Gervais A, et al. Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. J Acquir Immune Defic Syndr. 2012;61:581-7.
84. Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer. 2003;89:457-9. (Pubitemid 37026424)
85. Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS. 2002;16:531-6. (Pubitemid 34218847)
86. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009;21:445-54.
87. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027-32.
88. European AIDS Clinical Society: Cancer Screening Methods. Available at http://www.europeanaidsclinicalsociety.org/Guidelines/G2-p37.htm. Accessed March 2013.
89. New York State Health Department: Adult HIV Clinical Guidelines. Available at http://www.hivguidelines.org/clinical-guidelines/adults. Accessed March 2013.
90. • Sigel K, Dubrow R, Silverberg M, et al. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011;8:142-52. This recent article reviews existing evidence for cancer screening in HIV-infected patients. A paradigm for approaches to cancer screening is proposed and key research questions are identified, including the need for HIV-specific cancer screening guidelines.
91. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
92. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822-9. (Pubitemid 29231133)
93. Lam JM, Hoch JS, Tinmouth J, et al. Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS. 2011;25:635-42.
94. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009; 58:68-91.
95. Reinhold JP, Moon M, Tenner CT, et al. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol. 2005;100:1805-12. (Pubitemid 41648437)
96. • Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727-34. This study using the Danish nationwide HIV cohort and matched HIV-negative controls estimated mortality rates and population-attributable risk of death associated with smoking. The results suggested that HIV-infected smokers on HAART lose more life-years from smoking than HIV and have twice the population-attributable risk of death associated with smoking compared to controls.
97. Recommended adult immunization schedule: United States, 2012. Ann Intern Med. 2012; 156:211-217.
98. Drechsler H, Zhang S, Maalouf N, et al. Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART. [abstract R-260]. Presented at the 20th Conference for Retroviruses and Opportunistic Infections. Atlanta, GA; March 3-6, 2013.
99. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013. doi: 10.1093/cid/cit053.